Navigation Links
Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Date:11/18/2013

e no flu-like symptoms, no treatment-related elevations of liver enzymes greater than three times upper limit of normal, no abnormalities in renal function and no clinically meaningful changes in other laboratory values.

"We have now demonstrated that ISIS-APOCIIIRx has the ability to lower triglycerides equally well in patients with high to severely high triglycerides as well as in patients with high triglycerides and type 2 diabetes.  We have demonstrated that ISIS-APOCIIIRx can work equally well as a single agent and in combination with fibrates to produce significant reductions in apoC-III and triglycerides, and increases in HDL-C.  In addition, the observed positive effect of ISIS-APOCIIIRx treatment on lipid parameters, improvements in glucose control and trends toward improvements in insulin sensitivity, suggest that ISIS-APOCIIIRx could have a very attractive therapeutic profile for patients with severely high triglycerides, who often also have diabetes or metabolic syndrome," said Richard Geary, Ph.D., senior vice president of development at Isis. 

ISIS-APOCIIIRx is an antisense drug intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents.  ISIS-APOCIIIRx targets apoC-III, a protein produced in the liver that plays a central role in the regulation of serum triglycerides.  Humans who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease.  In clinical studies, patients with lower levels of apoC-III and triglycerides exhibit lower cardiovascular event rates.  Humans with elevated levels of apoC-III have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome.  In addition, the prevalence of type 2 diabetes i
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
(Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... VILLAGE, Nev., Nov. 2 PDL BioPharma, Inc. (PDL) ... on its previously disclosed $300 million securitization transaction intended ... royalties. Morgan Stanley & Co. Incorporated acted as ... terms of the securitization transaction, PDL sold to QHP ...
... Nov. 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... 30, 2009 on Monday, November 9, 2009, following the close of ... conference call at 5:00 p.m. Eastern Time on the same day ... call will be available for two weeks following the event. ...
Cached Medicine Technology:PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:5/30/2015)... (PRWEB) May 30, 2015 AVT, the ... quality assurance, is joining forces with leading proofing solutions ... to the worldwide printing market. , Under ... new software engine for its offline inspection solutions, which ... printing industry and its varying production workflow setups and ...
(Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
(Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
(Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
Breaking Medicine News(10 mins):Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3
... culture than nonaccredited facilities, according to a new study ... Joint Commission Journal on Quality and Patient Safety . ... more than 4,000 facilities across the U.S. identify Joint ... issues such as staffing, teamwork, training, nonpunitive responses to ...
... 27 (HealthDay News) -- Two genetic variations are linked to ... according to new research. Glaucoma affects about 2.2 million ... said in a news release. "Loss of vision from ... irreversible damage to the optic nerve," noted one expert, Dr. ...
... , FRIDAY, April 27 (HealthDay News) -- Electrocardiograph ... risk for sudden cardiac death, according to a new study. ... conducted EKGs on 586 of them based on medical history, ... were found to have a heart disorder known to cause ...
... , THURSDAY, April 26 (HealthDay News) -- Medicare, the federal ... hurtling toward the critical list, but most people don,t want ... new Harris Interactive/HealthDay poll finds. Eighty-three ... Medicare affordable and sustainable, and 51 percent think that "a ...
... , FRIDAY, April 27 (HealthDay News) -- Children who are ... the time they are 12 years old, according to a new ... and the United Kingdom said its findings, published online April 27 ... risk for this type of behavior. Examples of self-harming ...
... from the Research Institute of Wildlife Ecology (FIWI) of ... analysed a capture-recapture data set on common dormice ( ... this species. These small rodents are about the size ... ), but, unlike their rodent cousins, they hibernate ...
Cached Medicine News:Health News:NYUCN's Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes 2Health News:Research Gets Closer to Genetic Roots of Glaucoma 2Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 2Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 3Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 4Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:When to have kids: A complex question for hazel dormice 2
Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
Medicine Products: